Back to matchesWe found a matchYour institution may have rights to this item. Sign in to continue.TitleBortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF‐κB subunit RelA.Authorsvan Dijk, Anneke D.; Hoff, Fieke W.; Qiu, Yihua; Gerbing, Robert B.; Gamis, Alan S.; Aplenc, Richard; Kolb, E. Anders; Alonzo, Todd A.; Meshinchi, Soheil; Jenkins, Gaye N.; de Bont, Eveline S. J. M.; Kornblau, Steven M.; Horton, Terzah M.PublicationProteomics - Clinical Applications, 2022, Vol 16, Issue 2, p1ISSN1862-8346Publication typeArticleDOI10.1002/prca.202100072